Brain Shuttles: A New Path Into the Brain with James Gorman of the Wyss Institute
PreviousThe host of Business Trip, Matias Serebrinsky, interviews Wyss Senior Director of Translational R&D James (Jim) Gorman, M.D., Ph.D. Jim is a Principal Investigator of the Wyss Institute Brain Targeting Program (BTP). He leads a team developing new approaches to transport drugs through the blood-brain barrier (BBB) into the central nervous system.
In this episode, they discuss why the BBB blocks most modern drugs from entering the brain, how brain shuttles hijack natural transport pathways like the transferrin receptor to move drugs across the BBB, how new modalities that reach the brain can potentially treat diseases like Alzheimer’s, Parkinson’s, ALS, and lysosomal disorders, why the delivery route of shuttles enables IV or subcutaneous dosing instead of invasive intrathecal injections, how early data shows that shuttle-enabled antibodies clear amyloid faster, at lower doses, and with fewer side effects, and how the field is accelerating through a pre-competitive consortium model that lets multiple companies share shuttle platforms.